Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Expectations By $1.26 EPS

Indaptus Therapeutics (NASDAQ:INDP) issued its earnings results on Tuesday. The company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.36) by $1.26, FiscalAI reports.

Indaptus Therapeutics Stock Up 9.1%

Shares of INDP stock traded up $0.16 during mid-day trading on Tuesday, hitting $1.91. 15,801 shares of the stock were exchanged, compared to its average volume of 68,951. Indaptus Therapeutics has a 52-week low of $1.52 and a 52-week high of $47.60. The company has a market cap of $4.28 million, a PE ratio of -0.06 and a beta of 0.97. The firm has a fifty day moving average of $2.22 and a 200 day moving average of $2.72.

Wall Street Analyst Weigh In

INDP has been the topic of several analyst reports. Wall Street Zen downgraded Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by institutional investors and hedge funds.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.